Cyllene Therapeutics is a biotechnology company focused on non-replicating HSV-1 vector technology in neurology. Its HERMES platform delivers targeted neurotherapeutics to treat diseases of the peripheral and central nervous system. The company is developing EG110A, a DNA medicine candidate for severe neurogenic bladder conditions and multiple severe bladder diseases.
Investment Rounds
Capital activity and funding progression
Industries
Frequently Asked Questions
Where is Cyllene Therapeutics located?
Cyllene Therapeutics is located in Paris, France.
What industries does Cyllene Therapeutics operate in?
Cyllene Therapeutics operates in the following industries: biotechnology, biopharma, neurology, gene therapy.
Who are the investors in Cyllene Therapeutics?
The investors in Cyllene Therapeutics are: GordonMD Global Investments LP, Merck Ventures B.V., T. Andera Partners SAS, Bpifrance Investissement through its InnoBio 3 Fund, L.P., Lamond Ventures LLC.